[go: up one dir, main page]

UY26886A1 - Polimorfos de un análogo de epotilona - Google Patents

Polimorfos de un análogo de epotilona

Info

Publication number
UY26886A1
UY26886A1 UY26886A UY26886A UY26886A1 UY 26886 A1 UY26886 A1 UY 26886A1 UY 26886 A UY26886 A UY 26886A UY 26886 A UY26886 A UY 26886A UY 26886 A1 UY26886 A1 UY 26886A1
Authority
UY
Uruguay
Prior art keywords
epotilone
polymorphes
analog
methods
mixtures
Prior art date
Application number
UY26886A
Other languages
English (en)
Inventor
Zhenrong Guo
John D Dimarco
Jack Z Gougoutas
Imre M Vitez
Martha Davidovich
Michael Galolla
Timothy M Malloy
Denis Favreau
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22845469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY26886(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY26886A1 publication Critical patent/UY26886A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan, de acuerdo con la presente invención, dos polímeros cristalinos, denominados forma A y forma B respectivamente, así como mezclas de los mismos, de un análogo de epotilona representado por la fórmula. También se proporcionan métodos para formar los polimorfos novedosos, métodos terapéuticos que los utilizan y formas de dosificación farmacéutica que los contienen.
UY26886A 2000-08-16 2001-08-15 Polimorfos de un análogo de epotilona UY26886A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22559000P 2000-08-16 2000-08-16

Publications (1)

Publication Number Publication Date
UY26886A1 true UY26886A1 (es) 2002-03-22

Family

ID=22845469

Family Applications (1)

Application Number Title Priority Date Filing Date
UY26886A UY26886A1 (es) 2000-08-16 2001-08-15 Polimorfos de un análogo de epotilona

Country Status (41)

Country Link
US (4) US6689802B2 (es)
EP (1) EP1309597B1 (es)
JP (1) JP5046467B2 (es)
KR (1) KR100810342B1 (es)
CN (1) CN1269821C (es)
AR (1) AR034259A1 (es)
AT (1) ATE366735T1 (es)
AU (2) AU2001281082B2 (es)
BG (1) BG66132B1 (es)
BR (1) BR0113234A (es)
CA (1) CA2418109C (es)
CY (1) CY1107758T1 (es)
CZ (1) CZ305523B6 (es)
DE (1) DE60129334T2 (es)
DK (1) DK1309597T3 (es)
EE (1) EE05273B1 (es)
ES (1) ES2288518T3 (es)
GE (1) GEP20053495B (es)
HR (1) HRP20030190B1 (es)
HU (1) HU229314B1 (es)
IL (2) IL153993A0 (es)
IS (1) IS2845B (es)
LT (1) LT5138B (es)
LV (1) LV13032B (es)
MX (1) MXPA03001431A (es)
MY (1) MY134129A (es)
NO (1) NO328500B1 (es)
NZ (1) NZ523722A (es)
PE (1) PE20020290A1 (es)
PL (1) PL205628B1 (es)
PT (1) PT1309597E (es)
RO (1) RO123296B1 (es)
RU (1) RU2272039C2 (es)
SI (1) SI21100B (es)
SK (1) SK287876B6 (es)
TW (1) TWI320040B (es)
UA (1) UA75365C2 (es)
UY (1) UY26886A1 (es)
WO (1) WO2002014323A2 (es)
YU (1) YU12103A (es)
ZA (1) ZA200300522B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050043376A1 (en) * 1996-12-03 2005-02-24 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6242469B1 (en) * 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
HRP20030677B1 (hr) * 2001-01-25 2011-10-31 Bristol-Myers Squibb Company Postupci primjene analoga epotilona u liječenju karcinoma
CN1489466A (zh) * 2001-01-25 2004-04-14 ����˹�ж�-����˹˹������˾ 包含埃博霉素类似物的非肠道制剂
MXPA03007394A (es) 2001-02-20 2003-12-04 Bristol Myers Squibb Co Tratamiento de tumores refractarios mediante uso de derivados de epotilona.
CA2440555A1 (en) * 2001-03-14 2002-09-19 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
MXPA04008707A (es) * 2002-03-08 2006-03-08 Novartis Ag Combinaciones que comprenden derivados de epotilona y agentes de alquilacion.
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20090004277A1 (en) * 2004-05-18 2009-01-01 Franchini Miriam K Nanoparticle dispersion containing lactam compound
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
KR20070084325A (ko) * 2004-11-18 2007-08-24 브리스톨-마이어스 스큅 컴퍼니 익사베필론을 포함하는 장용성 코팅된 비드 및 그의 제조방법
US20060134214A1 (en) * 2004-11-18 2006-06-22 Ismat Ullah Enteric coated bead comprising epothilone or epothilone analog, and preparation and administration thereof
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
JP2008536479A (ja) 2005-02-11 2008-09-11 ユニバーシティ オブ サザン カリフォルニア ジスルフィド架橋を有するタンパク質の発現法
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
US7693596B2 (en) 2005-12-14 2010-04-06 Dell Products L.P. System and method for configuring information handling system integrated circuits
US7919108B2 (en) * 2006-03-10 2011-04-05 Cook Incorporated Taxane coatings for implantable medical devices
US20080286325A1 (en) * 2006-01-05 2008-11-20 Med Institute, Inc. Cyclodextrin elution media for medical device coatings comprising a taxane therapeutic agent
US7875284B2 (en) * 2006-03-10 2011-01-25 Cook Incorporated Methods of manufacturing and modifying taxane coatings for implantable medical devices
EP1994412A2 (en) 2006-03-31 2008-11-26 Brystol-Myers Squibb Company Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
EP2029156A4 (en) 2006-05-01 2010-07-21 Univ Southern California COMBINATION THERAPY FOR CANCER TREATMENT
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
BRPI0715963A2 (pt) * 2006-08-16 2013-08-06 Novartis Ag compostos orgÂnicos
US8463852B2 (en) * 2006-10-06 2013-06-11 Oracle International Corporation Groupware portlets for integrating a portal with groupware systems
WO2008103916A2 (en) * 2007-02-23 2008-08-28 The Trustees Of Columbia Univeristy In The City Of New York Compositions and methods for treating cancer or a neurotrophic disorder
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP2013527239A (ja) * 2010-06-01 2013-06-27 プラス・ケミカルス・エスアー イクサベピロンの固体形
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014009426A2 (en) 2012-07-13 2014-01-16 Innate Pharma Screening of conjugated antibodies
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
CN103183681B (zh) * 2013-03-06 2016-01-13 浙江海正药业股份有限公司 伊沙匹隆的新晶型及其制备方法
WO2014140300A1 (en) 2013-03-15 2014-09-18 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
WO2014202773A1 (en) 2013-06-20 2014-12-24 Innate Pharma Enzymatic conjugation of polypeptides
KR20160042871A (ko) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. 폴리펩티드의 효소적 콘쥬게이션
WO2019092148A1 (en) 2017-11-10 2019-05-16 Innate Pharma Antibodies with functionalized glutamine residues
CN115398011A (zh) 2020-01-31 2022-11-25 亚拉勒提治疗欧洲私人有限公司 用于预测癌症患者的伊沙匹隆反应性的方法
CN112375085A (zh) * 2020-11-30 2021-02-19 湖北宏中药业股份有限公司 一种伊沙匹隆反应液的高收率高纯度处理方法
CN112409366A (zh) * 2020-11-30 2021-02-26 湖北宏中药业股份有限公司 一种伊沙匹隆二聚体的高收率制备方法
CN112457320A (zh) * 2020-11-30 2021-03-09 湖北宏中药业股份有限公司 一种提高伊沙匹隆合成反应速率的方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1000809A (en) * 1960-11-02 1965-08-11 James Oakes & Company Riddings Pipe manufacture
DE2308418B2 (de) * 1972-06-21 1976-04-08 Petzetakis, Aristovoulos George, Moschaton, Piräus (Griechenland) Verfahren und vorrichtung zum herstellen eines insbesondere grosskalibrigen rohres aus thermoplastischem kunststoff
JPS5240337B2 (es) * 1973-01-29 1977-10-12
SE386365B (sv) * 1973-07-25 1976-08-09 L Brendling Behallare av plast, gummi eller annat bojligt material, spec. avsedd for uppsamling av urin och/eller fekalier
JPS6398413A (ja) * 1986-10-15 1988-04-28 Smc Corp 二重管およびその連続製造法
DE3927569A1 (de) * 1989-08-21 1991-02-28 Fritz Egger Gmbh Elektroabscheider zum abscheiden von schwebstoffen aus gasen
DE3939714A1 (de) * 1989-12-01 1991-06-06 Baedje K H Meteor Gummiwerke Schlauch
WO1991011012A1 (en) * 1990-01-05 1991-07-25 Orscheln Co. Flexible synthetic plastic conduit
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
DE4206096A1 (de) * 1992-02-27 1993-09-02 Wolf Woco & Co Franz J Koaxialrohr
US6288237B1 (en) 1995-11-17 2001-09-11 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epothilons C and D, preparation and compositions
DE19639456A1 (de) 1996-09-25 1998-03-26 Biotechnolog Forschung Gmbh Epothilon-Derivate, Herstellung und Mittel
DE19542986A1 (de) 1995-11-17 1997-05-22 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Verwendung
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
NZ334821A (en) 1996-08-30 2000-12-22 Novartis Ag Method for producing epothilones
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
CN100344627C (zh) 1996-11-18 2007-10-24 生物技术研究有限公司(Gbf) 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6441186B1 (en) 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
NZ337195A (en) * 1997-02-25 2001-05-25 Biotechnolog Forschung Gmbh Epothilones with a modified side chain
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
DE59805900D1 (de) 1997-04-18 2002-11-14 Studiengesellschaft Kohle Mbh Selektive olefinmetathese von bi- oder polyfunktionellen substraten in komprimiertem kohlendioxid als reaktionsmedium
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
AU9340998A (en) 1997-08-09 1999-03-01 Schering Aktiengesellschaft New epothilone derivatives, method for producing same and their pharmaceutical use
DE19747580A1 (de) 1997-10-28 1999-04-29 Siemens Ag Rangierfeld mit Anschlußleiste
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
EP1052974B1 (en) 1998-02-05 2009-05-20 Novartis AG Pharmaceutical formulation containing epothilone
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
DE19807505A1 (de) 1998-02-21 1999-08-26 Roland Man Druckmasch Bogenrotationsdruckmaschine mit Druckeinheiten für den Mehrfarbendruck und wenigstens einer Beschichtungseinheit
ATE307123T1 (de) 1998-02-25 2005-11-15 Sloan Kettering Inst Cancer Synthese von epothilonen, ihren zwischenprodukten und analogen verbindungen
FR2775187B1 (fr) 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
AU5036999A (en) 1998-06-30 2000-01-17 Schering Aktiengesellschaft Epothilon derivatives, their preparation process, intermediate products and their pharmaceutical use
WO2000009317A1 (en) * 1998-08-12 2000-02-24 Proteus Inc. Ribbed core dual wall structure
EP1140944B1 (en) 1998-12-22 2003-08-27 Novartis AG Epothilone derivatives and their use as antitumor agents
RU2242229C2 (ru) * 1999-01-19 2004-12-20 Новартис Аг Применение эпотилонов для лечения рака
PE20010116A1 (es) 1999-04-30 2001-02-15 Schering Ag Derivados de 6-alquenil-, 6-alquinil- y 6-epoxi-epotilona, procedimientos para su preparacion
US6605559B1 (en) * 1999-09-29 2003-08-12 Daihatsu Motor Co., Ltd. Dimethyl ether reforming catalyst
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
EP1353668B1 (en) 2001-01-25 2008-03-19 Bristol-Myers Squibb Company Processes for the preparation of pharmaceutical preparations containing epothilone analogues for the treatment of cancer
CN1489466A (zh) * 2001-01-25 2004-04-14 ����˹�ж�-����˹˹������˾ 包含埃博霉素类似物的非肠道制剂
US9317043B2 (en) 2013-12-19 2016-04-19 Google Inc. Path based power generation control for an aerial vehicle

Also Published As

Publication number Publication date
SI21100A (sl) 2003-06-30
US7153879B2 (en) 2006-12-26
EE200300063A (et) 2004-12-15
CA2418109A1 (en) 2002-02-21
CZ305523B6 (cs) 2015-11-18
GEP20053495B (en) 2005-04-25
HRP20030190B1 (en) 2011-07-31
UA75365C2 (en) 2006-04-17
BG107467A (bg) 2003-09-30
PT1309597E (pt) 2007-08-22
MXPA03001431A (es) 2004-05-04
CA2418109C (en) 2011-09-27
CY1107758T1 (el) 2013-06-19
WO2002014323A3 (en) 2002-05-02
SI21100B (sl) 2009-12-31
ATE366735T1 (de) 2007-08-15
PL365610A1 (en) 2005-01-10
DE60129334D1 (en) 2007-08-23
USRE39251E1 (en) 2006-08-29
LT5138B (lt) 2004-06-25
US20020188014A1 (en) 2002-12-12
LT2003017A (en) 2004-03-25
BR0113234A (pt) 2004-02-25
NO20030707L (no) 2003-04-15
AU8108201A (en) 2002-02-25
CN1468243A (zh) 2004-01-14
SK287876B6 (sk) 2012-02-03
EP1309597B1 (en) 2007-07-11
HK1052010A1 (en) 2003-08-29
ES2288518T3 (es) 2008-01-16
SK1342003A3 (en) 2003-09-11
HUP0300826A2 (hu) 2003-09-29
US6982276B2 (en) 2006-01-03
CZ2003418A3 (cs) 2004-01-14
AU2001281082B2 (en) 2007-01-04
DK1309597T3 (da) 2007-10-22
US6689802B2 (en) 2004-02-10
AR034259A1 (es) 2004-02-18
EP1309597A2 (en) 2003-05-14
JP5046467B2 (ja) 2012-10-10
PL205628B1 (pl) 2010-05-31
US20040157897A1 (en) 2004-08-12
IS2845B (is) 2013-08-15
ZA200300522B (en) 2004-04-20
NO20030707D0 (no) 2003-02-14
HUP0300826A3 (en) 2005-05-30
HRP20030190A2 (en) 2003-04-30
BG66132B1 (bg) 2011-06-30
IL153993A0 (en) 2003-07-31
DE60129334T2 (de) 2008-04-03
IS6714A (is) 2003-02-11
HU229314B1 (en) 2013-10-28
IL153993A (en) 2009-07-20
TWI320040B (en) 2010-02-01
YU12103A (sh) 2006-08-17
NO328500B1 (no) 2010-03-01
MY134129A (en) 2007-11-30
KR20030022411A (ko) 2003-03-15
JP2004506638A (ja) 2004-03-04
NZ523722A (en) 2005-04-29
US20060063815A1 (en) 2006-03-23
RU2272039C2 (ru) 2006-03-20
RO123296B1 (ro) 2011-06-30
CN1269821C (zh) 2006-08-16
WO2002014323A2 (en) 2002-02-21
LV13032B (en) 2003-12-20
KR100810342B1 (ko) 2008-03-07
EE05273B1 (et) 2010-02-15
PE20020290A1 (es) 2002-04-03

Similar Documents

Publication Publication Date Title
UY26886A1 (es) Polimorfos de un análogo de epotilona
CO6362017A2 (es) Peptidos antivirales terapeuticos
CR6726A (es) Compuestos azapoliciclicos condensados con arilo
UY27427A1 (es) Nuevas dihidro-pteridinonas, procedimientos para su preparación y su utilización como medicamentos
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
ATE478685T1 (de) Prodrugs mit neuen biospaltbaren verbindern
AR077415A2 (es) Derivados de oxindol sustituido , medicamentos que los comprenden y uso de los mismos
UY27226A1 (es) Pirazolopirimidinas como agentes terapéuticos
CO5271715A1 (es) 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
SE0302811D0 (sv) Novel compounds
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
AR048741A1 (es) Derivados de omega-carboxiaril difenil urea sustituida
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CO6150138A2 (es) Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc
SV1999000047A (es) Nuevas dihidropirimidinas fef. lea 32792-sv
AR027355A1 (es) Acidos tiazolidincarboxilicos
UY28859A1 (es) Antagonistas de cgrp seleccionados, procedimiento para su preparación así como su uso como medicamento
UY28348A1 (es) Compuestos novedosos
UY27455A1 (es) Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
UY27018A1 (es) Derivados de la pirimidina
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR047922A1 (es) Nuevos derivados de pentafluorsulfanilo, su obtencion y su utilizacion como agentes farmaceuticos
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
UY27903A1 (es) Derivados de indolinona sustituidos en posición 6, su preparación y su uso como medicamentos.
ECSP066964A (es) Nuevos beta-agonistas, procedimiento para su preparación y su uso como medicamentos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20141001